Effects of Terlipressin on Blood Loss and Transfusion Requirements During Major Liver Resection.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02588716|
Recruitment Status : Completed
First Posted : October 28, 2015
Last Update Posted : December 27, 2017
|Condition or disease||Intervention/treatment||Phase|
|Hepatectomy, Surgical Blood Loss, Terlipressin||Drug: Terlipressin Drug: normal saline||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||84 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Effects of Terlipressin on Blood Loss and Transfusion Requirements During Major Liver Resection.|
|Study Start Date :||September 2015|
|Actual Primary Completion Date :||March 2016|
|Actual Study Completion Date :||December 2016|
Active Comparator: Terlipressin
Terlipressin will be given at the beginning of surgery as an initial bolus dose of (1 mg over 30 mins) followed by a continuous infusion of 2μg/kg/h to be continued throughout the surgery then gradually withdrawn over 4 hours
Terlipressin will be given as an intravenous injection of 2μg/kg/h to be continued throughout the surgery and weaned off over four hours postoperatively.
Other Name: glipressin
Placebo Comparator: Control
same volumes of normal saline with the same rate of infusion, throughout the operation then gradually withdrawn over 4 hours.
Drug: normal saline
Same volumes of normal saline infusion, throughout the operation then gradually withdrawn over 4 hours.
- blood loss [ Time Frame: intraoperative period ]blood loss in ml
- blood units transfused [ Time Frame: intraoperative period ]number of packed RBCs units transfused
- lactate level [ Time Frame: at start and end of resection ]lactate level in blood gas sample in mmol/L
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02588716
|Assiut University hospital|
|Assiut, Asyut Governorate, Egypt, 11111|